Reported Sunday, Alteogen Secures Exclusive License Deal With Daiichi Sankyo To Develop Subcutaneous Version Of ENHERTU Using Hybrozyme Technology
Reported Sunday, Alteogen Secures Exclusive License Deal With Daiichi Sankyo To Develop Subcutaneous Version Of ENHERTU Using Hybrozyme Technology
週日報道，阿爾特奧根與大塚三共同達成獨家許可協議，利用Hybrozyme技術開發ENHERTU的皮下版本。
Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme Technology, to develop and commercialize a subcutaneous version of ENHERTU (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody drug conjugate (ADC) that has been jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
根據協議條款，大塚三將收購全球使用ALt-B4的權利，該產品是阿爾特奧根的新型透明質酸酶，利用Hybrozyme技術開發和商業化ENHERTU的皮下版本（fam-trastuzumab deruxtecan-nxki），這是一個HER2靶向抗體藥物複合物（ADC），由大塚三和阿斯利康共同開發和商業化。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間